Great work. The clear objective of making timely progress is reassuring, as is the absence of any adverse reactions (the endpoint of a phase 1 trail).
Ann: Amplia Initiates Multiple Dose Study of AMP945, page-2
Add ATX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
6.3¢ |
Change
0.003(5.00%) |
Mkt cap ! $17.11M | |||
| Open | High | Low | Value | Volume |
| 6.0¢ | 6.4¢ | 5.9¢ | $16.55K | 273.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10753 | 6.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.7¢ | 2424 | 1 |
View Market Depth
| Last trade - 15.56pm 23/05/2024 (20 minute delay) ? |
|
|||||
|
Last
6.4¢ |
Change
0.003 ( 6.67 %) |
||||
| Open | High | Low | Volume | ||
| 6.0¢ | 6.4¢ | 6.0¢ | 3683 | ||
| Last updated 15.26pm 23/05/2024 ? | |||||
| ATX (ASX) Chart |